Biologics Contract Manufacturing Market Size to Hit USD 58 Billion by 2035 | Exclusive Report by Roots Analysis
Biologics contract manufacturing market size was valued at USD 22.2 billion in 2024 and likely to hit over USD 58 billion by 2035.
The specificity, efficacy and safety-related advantages of biologics have captured the attention of industry stakeholders and consumers. Presently, a variety of biologics is being developed for a wide range of diseases, including those characterized by large target patient populations and rare disease indications, which are typically associated with smaller target patient populations.
The overall success of biologics has resulted in a growing demand from patients, insurers and government bodies across the world. Owing to their therapeutic potential and target specificity, we anticipate the demand for such drug products to persist over the coming years.
According to Roots Analysis, the biologics contract manufacturing market size was valued at USD 22.2 billion in 2024 and likely to hit over USD 58 billion by 2035, growing at a CAGR of 9.12 during the forecast period 2023 to 2035
The biopharmaceutical contract manufacturing market is highly competitive, and in such a fragmented (competitive) market, possession of advanced capabilities and specialized expertise serves as an important differentiating factor.
Thus, in order to meet the growing requirements of their clients and to improve their capabilities, several contract manufacturers have entered into partnerships with each other. This allows CMOs to offer a wide range of services to their clients and helps to maintain a long-term relationship with them, which are some of the key drivers anticipated to boost the market growth.
By type of service offered, API manufacturing segment is expected to account for the largest share of the global biologics contract manufacturing market
The large share of this market is mainly attributed to the significant capital investments, including facility cost, material cost and other ancillary expenses are associated with the manufacturing of biologics, considering this stakeholders rely on the expertise of CMOs for API production.
By type of biology manufactured, antibodies hold a significant market share during the forecast period
§ The demand for antibodies in the biologics contract manufacturing market is increasing globally due to their ability to target a broad range of target antigens, for instance cancer cells, immunosuppressor and immunomodulatory molecules.
§ Additionally, more than 100 antibodies have been approved across the globe and an increasing number of clinical trials related to antibodies are also underway. Furthermore, the increasing prevalence of cancer is projected to increase the demand for monoclonal antibodies as they aid in the treatment of cancer.
Biologics Contract Manufacturing Market – Regional Analysis
North America and Europe are currently dominating the biologics contract manufacturing market. This can be attributed to the fact that the number of manufacturing facilities in these regions is relatively higher.
Additionally, the market in Asia-Pacific is expected to grow at a CAGR of 11.4%, as the manufacturers based in the region are continuously expanding their capabilities / capacities over the last few years, specifically post the COVID-19 pandemic. Based on the aforementioned reasons, we are led to believe that the general / expected trend will evolve over the coming years, with Asia-Pacific capturing a slightly higher market share than North America and Europe.
Key Market Players
AcuraBio, AGC Biologics, Boehringer Ingelheim, Catalent, Cell Therapies, Celltrion, Cytiva, Charles River Laboratories, FUJIFILM Diosynth Biotechnologies, KBI Biopharma, Kemwell Biopharma, Lonza, Miltenyi Biotec, Minaris Regenerative Medicine, Novasep, Olon, Patheon, Piramal Pharma Solutions, Samsung Biologics, Sandoz, Takara Bio, Vetter Pharma, Wuxi Biologics.
Biologics Contract Manufacturing Market – Key Segments
by Type of Service Offered
§ API Manufacturing
§ FDF Manufacturing
by Type of Biologic Manufactured
§ Antibodies
§ Cell Therapies
§ Vaccines
§ Other Biologics
by Type of Expression System Used
§ Mammalian Expression Systems
§ Microbial Expression Systems
§ Other Expression Systems
by Scale of Operation
§ Preclinical / Clinical
§ Commercial
by Company Size
§ Small
§ Mid-sized
§ Large and Very Large
by Key Geographical Regions
§ North America
§ Europe
§ Asia-Pacific
§ Latin America
§ Middle East and North Africa
by Leading Players
§ BioXcellence
§ Catalent Biologics
§ FUJIFILM Diosynth Biotechnologies
§ Lonza
§ Samsung BioLogics
§ WuXi Biologics
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Email: sales@rootsanalysis.com
